Page 9 - Aurobindo Pharma

Aurobindo Pharma gets warning letter from USFDA for API facility

Aurobindo Pharma on Friday said it has received a warning letter from the US health regulator for its Hyderabad-based Unit I, an API manufacturing facility.

Aurobindo Pharma arm CuraTeQ expands scope of distribution pact with Orion

Aurobindo Pharma on Tuesday said its subsidiary CuraTeQ Biologics has expanded the scope of its marketing and distribution agreement with Orion Corporation (Orion)

Sensex plunges 949pts, Nifty ends 285pts lower; Airtel, RIL, IT shares drag

The broader markets also weakened towards the end of the trade, and the BSE Midcap and Smallcap indices ended with a loss of 1.4 per cent each

Stocks to Watch: Hero MotoCorp, Aurobindo, Neogen, SPARC, telecom shares

Telecom shares may be in demand on credit of bank guarantee to the telcos

Aurobindo Pharma, Unichem Laboratories recall products in US market

Aurobindo Pharma and Unichem Laboratories are recalling different products in the US market, the world's largest market for medicines, due to manufacturing issues. As per the latest enforcement report issued by the US Food and Drug Administration (USFDA), Aurobindo's US-based unit is recalling 7,296 containers of hypertension drug Carvedilol tablets. The affected lot contains 6.25 mg Carvedilol tablets, which have been produced in India and distributed in the US by Princeton-based Aurobindo Pharma USA Inc. The company is recalling the lot due to "failed impurities/degradation specifications", the US health regulator noted in the report. Aurobindo initiated the nationwide the recall on November 15 this year, it added. Another domestic drug maker Unichem Laboratories is recalling 1,284 bottles of Topiramate tablets, used to treat epilepsy (seizures) and to prevent migraines. It is also used in the treatment of Lennox-Gastaut syndrome (a rare, but severe form of epilepsy that starts

Hero MotoCorp, Lupin, Colgate, Aurobindo, Amara Raja hit 52-week lows

In past four trading days, the S&P BSE Sensex has tanked 4 per cent or 2,412 points on concerns about European Covid-19 curbs and on risk of the US Federal Reserve speeding up stimulus withdrawal.

Strong product pipeline, valuations keep street positive on Aurobindo

The company delivered a muted show in the September quarter

Britannia, Aurobindo, Ujjivan SFB look weak on charts post Q2 results

Sobha Ltd, however, is expected to surge up to 14% indicates the daily chart.

Stocks to Watch: RIL, Aurobindo, BHEL, M&M, Jet Airways, IDFC, PowerGrid

FII fund flows, corporate earnings and ongoing IPOs likely to be in focus today

Aurobindo Pharma Q2 net profit declines nearly 14% to Rs 697 crore

The drug firm on Monday reported a decline in its consolidated net profit

Stocks to Watch: Aurobindo, Divi's, PTC, Sun Tv, Muthoot Fin, realty shares

Realty stocks on the back of PAG taking a contra call on the sector and corporate earnings will be in focus today

Q2 preview: Non-Covid revenues to hint at normalisation for healthcare cos

Companies may, however, report sequential drop in numbers as Q1FY22 coincided with outbreak of second Covid wave, say brokerages

Sensex snaps 4-day losing streak, ends 534 pts up; Nifty tad below 17,700

Stock market LIVE: Sectorally, all the indices were in the green, led by the Nifty Realty index (up 3.5 per cent)

Drug makers Glenmark, Aurobindo Pharma recall products in US market

Glenmark and Aurobindo Pharma are recalling multiple products in the US market due to various reasons like deviation from standard manufacturing protocols and presence of foreign substance

N Govindarajan steps down as Aurobindo Pharma managing director

Govindarajan has decided to step down due to "personal reasons", Aurobindo Pharma said in a regulatory filing

Aurobindo Pharma gets USFDA nod for cancer treatment injection

Drug firm Aurobindo Pharma on Friday said its arm Eugia Pharma Specialities has received approval from the US health regulator for Cyclophosphamide injection, used in the treatment of several types of cancer. The company's subsidiary "Eugia Pharma Specialities Ltd has received a 505(b)(2) NDA approval from the US Food & Drug Administration (USFDA) for its Cyclophosphamide Injection 500 mg/2.5 mL and 1 g/5 mL vial," Aurobindo Pharma said in a regulatory filing. The product will be available in ready-to-use injection preparation, it added. "The product shall be launched in the US market in the near term and will be manufactured in Eugia's manufacturing facility in India," Aurobindo Pharma said. According to IQVIA, the approved product has an addressable market size of USD 170 million for the twelve months ending June 2021, it added. Cyclophosphamide Injection is indicated for malignant lymphomas, multiple myeloma, leukemia, mycosis fungoides, neuroblastoma, adenocarcinoma of the ...

Two stock recommendations from Osho Krishan of Anand Rathi

Aurobindo Pharma has corrected over 35 per cent from its lifetime high and has plunged below all its major exponential moving averages

Aurobindo Pharma calls off agreement to pick stake in Cronus; stock up 6%

Aurobindo Pharma, on August 12, 2021, had entered into binding agreements with Cronus Pharma Specialities India Private Limited for acquisition of 51 per cent ownership

Stocks to watch: Nuvoco Vistas, Auro Pharma, Ujjivan SFB, Adani Group cos

Market regulator Sebi kept the proposed Rs 4,500-crore initial share-sale of edible oil major Adani Wilmar in "abeyance"

Aurobindo Pharma's Rs 450-cr deal to acquire 51% in Cronus Pharma cancelled

Aurobindo Pharma Ltd on Friday said its Rs 450-crore deal to acquire 51 per cent stake in Cronus Pharma Specialities India Pvt Ltd (Cronus) has been cancelled